In patients with long-standing T1D and double diabetes, the use of novel incretin analogs (semaglutide and tirzepatide) has been associated with remarkable clinical benefits, which mostly consist of clinically meaningful improvement of glucose control and substantial weight loss. The gene discussed is GCG; the disease is type 1 diabetes mellitus.